Research on the humanized monoclonal antibody Nimotuzumab developed by the Molecular Immunology Center (CIM) received the special prize granted by the Cuban Ministry of Science, Technology and Environment (CITMA) for being the most scientifically relevant work of the year.
According to information released by the CIM on its official Twitter account ¨ the Citma Special Prize was awarded the title &Repositioning of the Cuban humanized monoclonal antibody Nimotuzumab in the treatment of patients with Covid-19."
In this regard, Dr. Tania Crombet, Director of Clinical Research at the CIM, pointed out that Nimotuzumab was used in the medication of these patients, who improved their ventilatory function and registered a decrease in inflammation markers.
With the application of this drug in patients afflicted with Covid-19, generated by SARS-Cov-2, an 80 percent radiological recovery or stabilization of multifocal interstitial pneumonia was also evidenced on the seventh day of treatment.
Likewise, Dr. Crombet demonstrated evidence of prevention or improvement of fibrotic lesions and a high rate of rehabilitation in seriously ill patients, she noted.According to the specialist, unlike other innovative molecules used against Covid-19, this monoclonal antibody could play an important role as an anti-inflammatory, and significantly influence the restoration of the coagulation disorder that accompanies this disease, in addition to preventing or reversing thepulmonary fibrosis.
The specialist also pointed out that these benefits are attributed to the fact that the Epidermal Growth Factor is one of the central proteins involved in cell proliferation and tissue repair that occurs as a consequence of the damage caused by the virus.
CubaPLUS Latinos
CubaPLUS Guyana
CubaPLUS Travel